AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation

RecruitingNAAges 19 Years - anyAllSeoul National University Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This is a multicenter, randomized controlled trial to compare the recurrence of 1-year atrial arrhythmia after catheter ablation of atrial fibrillation (AF) between pulmonary vein isolation (PVI) and PVI with additional left atrial (LA) substrate modification based on the left atrial low-voltage area (LA LVA) in patients with persistent AF who had a moderate burden of LVA in LA (1cm2 to \<30%).

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Ages eligible for the study: 19 years or older Inclusion criteria: 1. Patients with symptomatic persistent AF who undergo AF catheter ablation due to continued AF even after anti-arrhythmic agents or 2. Patients with a burden of LA LVA (scar zone) of 1cm2 or more and less than 30% in 3D voltage mapping before the index catheter ablation are included in the randomized assignment group when performing catheter ablation in satisfaction with 1) 4\) Patients with an LVA of \<1cm2 or โ‰ฅ30% are recruited as a registry. Exclusion criteria: 1. Patients with LA anteroposterior diameter of more than 55 mm 2. Patients with prior AF-related catheter ablation or surgery 3. Patients whose exact LVA burden cannot be calculated because high-quality 3D voltage mapping cannot be obtained during the procedure. 4. Inability or unwillingness to receive anticoagulation (heparin or oral anticoagulation) 5. Known severe left ventricular systolic dysfunction (ejection fraction \<35%) 6. Patients with severe structural heart disease (severe mitral regurgitation, hypertrophy cardiomyopathy, other severe valvular heart diseases) 7. Patients with intracardiac thrombus 8. Patients with prior cardiac surgery 9. Patients who had a myocardial infarction or underwent percutaneous coronary intervention within three months 10. Patients who had a stroke or transient ischemic attack within 6 months 11. Patients who had a planned operation or procedure for the cardiovascular system 12. Patients with intractable hypertension or uncontrolled thyroid disease 13. Patients who need dialysis due to end-stage renal disease or who are scheduled for dialysis 14. Patients who are currently pregnant or are likely to be pregnant within the study period 15. Patients who are taking immunosuppressive drugs or had undergone chemotherapy for cancer, autoimmune disease, transplant, etc 16. Patients whose life expectancy is less than 1 year
๐Ÿ’Š

What it tests

  • LVA-guided LA substrate modification
๐Ÿ“

Where

1 site
Seoul National University Hospital
Seoul, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy